Spots Global Cancer Trial Database for Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
Official Title: Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab in Patients With Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia After Allogeneic Stem Cell Transplantation
Study ID: NCT03982992
Study Description
Brief Summary: This phase 2 study is designed to evaluate the safety, tolerability and efficacy of allogeneic donor lymphocyte infusions (DLI) combined with the bispecific T cell engager blinatumomab in B-precursor ALL patients who have mixed chimerism (MC) or are MRD-positive after allogeneic SCT and are refractory to at least one MRD- or MC-targeted therapy (i.e. blinatumomab, DLI, tyrosine kinase inhibitors or other agents).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Klinikum der Universität München, Munich, , Germany
Contact Details
Name: Marion Subklewe, MD
Affiliation: Klinikum der Universität München
Role: PRINCIPAL_INVESTIGATOR
Name: Christian Schmidt, MD
Affiliation: Klinikum der Universität München
Role: PRINCIPAL_INVESTIGATOR
Name: Sascha Haubner, MD
Affiliation: Klinikum der Universität München
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
